Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

AKT/PKB signaling: navigating downstream

Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092

The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation

DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645

A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance

Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.002 · Cited by 3,165

mTOR Signaling in Growth Control and Disease

Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509

MTOR: a pharmacologic target for autophagy regulation

Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126

PI3K and cancer: lessons, challenges and opportunities

Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,762

Rapamycin: one drug, many effects

Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287

Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities

Menzies, F. M., Fleming, A., Caricasole, A., Bento, C. F., Andrews, S. P., Ashkenazi, A., Füllgrabe, J., Jackson, A., Jimenez Sanchez, M., Karabiyik, C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.01.022 · Cited by 1,134

mTOR kinase structure, mechanism and regulation

Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075

Development of PI3K inhibitors: lessons learned from early clinical trials

Rodon, J. A., Dienstmann, R., Serra, V., & Tabernero, J. M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 787

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

Paplomata, E., & O'Regan, R. M. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014530023 · Cited by 610

SREBPs: metabolic integrators in physiology and metabolism

Jeon, T.-I., & Osborne, T. F. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.10.004 · Cited by 464

Breast Cancer Treatments: Updates and New Challenges

Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 553

mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin

Kang, S. A., Pacold, M. E., Cervantes, C., Lim, D., Lou, H. J., Ottina, K. A., Gray, N. S., Turk, B. E., Yaffe, M. B., & Sabatini, D. M. (2013) · Science · doi:10.1126/science.1236566 · Cited by 420

Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease

Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 410

Targeting RTK Signaling Pathways in Cancer

Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 402

Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease

Harris, P. C., & Torres, V. E. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72272 · Cited by 351

Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases

Watanabe, S., Kawamoto, S., Ohtani, N., & Hara, E. (2017) · Cancer Science · doi:10.1111/cas.13184 · Cited by 321

Growing knowledge of the mTOR signaling network

Huang, K., & Fingar, D. C. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.09.011 · Cited by 310

mTOR inhibitors in cancer therapy

Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Evers, B. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.005 · Cited by 298

Autophagy in Vascular Disease

Meyer, G. R. Y. D., Grootaert, M. O. J., Michiels, C. F., Kurdi, A., Schrijvers, D. M., & Martinet, W. (2015) · Circulation Research · doi:10.1161/circresaha.116.303804 · Cited by 292

mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis

Iglesias-Bartolome, R., Patel, V., Cotrim, A., Leelahavanichkul, K., Molinolo, A. A., Mitchell, J. B., & Gutkind, J. S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.06.007 · Cited by 284

Selective autophagy degrades DICER and AGO2 and regulates miRNA activity

Gibbings, D., Mostowy, S., Jay, F., Schwab, Y., Cossart, P., & Voinnet, O. (2012) · Nature Cell Biology · doi:10.1038/ncb2611 · Cited by 257

Molecular and Cellular Mechanisms of Action of Tumour Suppressor GAS5 LncRNA

Pickard, M. R., & Williams, G. T. (2015) · Genes · doi:10.3390/genes6030484 · Cited by 229

PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances

So, L., & Fruman, D. A. (2012) · Biochemical Journal · doi:10.1042/bj20112092 · Cited by 220

Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer

Nunnery, S. E., & Mayer, I. A. (2020) · Drugs · doi:10.1007/s40265-020-01394-w · Cited by 225

HSF1: Guardian of Proteostasis in Cancer

Dai, C., & Sampson, S. B. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.011 · Cited by 221

Roles of mTOR complexes in the kidney: implications for renal disease and transplantation

Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208

Pituitary Carcinoma: Difficult Diagnosis and Treatment

Heaney, A. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2031 · Cited by 200

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

Lin, Y., Wang, X., & Jin, H. (2014) · Europe PMC (PubMed Central) · Cited by 198

Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1

Li, H., Li, X., Liu, S., Guo, L., Zhang, B., Zhang, J., & Ye, Q. (2017) · Hepatology · doi:10.1002/hep.29360 · Cited by 197

Estrogen receptor signaling as a target for novel breast cancer therapeutics

Renoir, J., Marsaud, V., & Lazennec, G. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.018 · Cited by 197

The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis

Lawrence, J., & Nho, R. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030778 · Cited by 183

Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins

Schreiber, K. H., Ortiz, D., Academia, E. C., Anies, A. C., Liao, C., & Kennedy, B. K. (2015) · Aging Cell · doi:10.1111/acel.12313 · Cited by 183

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

Costa, R. L. B., Shah, A. N., Santa-Maria, C. A., Cruz, M. R. D. S., Mahalingam, D., Carneiro, B. A., Chae, Y. K., Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.010 · Cited by 177

Treating Breast Cancer in the 21st Century: Emerging Biological Therapies

Tinoco, G., Warsch, S., Glück, S., Avancha, K. K. V. R., & Montero, A. J. (2013) · Journal of Cancer · doi:10.7150/jca.4925 · Cited by 179

The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond

Wander, S. A., Levis, M. J., & Fathi, A. T. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714532123 · Cited by 166

mTOR signaling in tumorigenesis

Xu, K. L., Liu, P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.10.007 · Cited by 167

Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives

Ong, P. S., Wang, L. Z., Dai, X., Tseng, S. H., Loo, S. J., & Sethi, G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00395 · Cited by 162

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer

Yen, T., Wang, T., Fader, A. N., Shih, I., & Gaillard, S. L. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000585 · Cited by 167

Sirt3 confers protection against neuronal ischemia by inducing autophagy: Involvement of the AMPK-mTOR pathway

Dai, S., Chen, T., Li, X., Yue, K., Luo, P., Yang, L., Zhu, J., Wang, Y., Fei, Z., & Jiang, X. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.005 · Cited by 158

p27 as a Transcriptional Regulator: New Roles in Development and Cancer

Razavipour, S. F., Harikumar, K. B., & Slingerland, J. M. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3663 · Cited by 152

mTOR kinase inhibitors as potential cancer therapeutic drugs

Sun, S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.017 · Cited by 152

Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance

Xu, M., Hu, Y. B., Ding, W., Li, F., Lin, J., Wu, M., Wu, J., Wen, L., Qiu, B., Wei, P., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120308 · Cited by 145

Overview of Research into mTOR Inhibitors

Mao, B., Zhang, Q., Ma, L., Zhao, D., Zhao, P., & Yan, P. (2022) · Molecules · doi:10.3390/molecules27165295 · Cited by 155

Estradiol inhibits osteoblast apoptosis via promotion of autophagy through the ER–ERK–mTOR pathway

Yang, Y., Chen, K., Li, B., Chen, J.-W., Zheng, X., Wang, Y., Jiang, S., & Jiang, L. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0867-x · Cited by 143

Management of toxicity to isoform α-specific PI3K inhibitors

Nunnery, S. E., & Mayer, I. A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz440 · Cited by 137

The heat-shock, or HSF1-mediated proteotoxic stress, response in cancer: from proteomic stability to oncogenesis

Dai, C. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0525 · Cited by 134

The La-Related Proteins, a Family with Connections to Cancer

Stavraka, C., & Blagden, S. P. (2015) · Biomolecules · doi:10.3390/biom5042701 · Cited by 128

Insights into molecular therapy of glioma: current challenges and next generation blueprint

Rajesh, Y., Pal, I., Banik, P., Chakraborty, S., Borkar, S. A., Dey, G., Mukherjee, A., & Mandal, M. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.167 · Cited by 134

Chronic mTOR inhibition in mice with rapamycin alters T , B , myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice

Hurez, V. J., Dao, V. A., Liu, A., Pandeswara, S., Gelfond, J., Sun, L., Bergman, M. A., Orihuela, C. J., Galván, V., Padron, A. S., et al. (2015) · Aging Cell · doi:10.1111/acel.12380 · Cited by 129

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

Mitchell, R., Hopcroft, L. E. M., Baquero, P., Allan, E. K., Hewit, K. D., James, D. T., Hamilton, G. M., Mukhopadhyay, A., O’Prey, J., Hair, A., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx236 · Cited by 129

SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway

Zhou, C., Liu, C., Liu, W., Chen, W., Yin, Y., Li, C.-W., Hsu, J. L., Sun, J., Zhou, Q., Li, H., et al. (2020) · Theranostics · doi:10.7150/thno.42869 · Cited by 121

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer

Alves, C. L., & Ditzel, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054522 · Cited by 126

Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism

Patel, A., Tsilioni, I., Leeman, S. E., & Theoharides, T. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604992113 · Cited by 123

Hypoxia signaling in cancer: Implications for therapeutic interventions

Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119

Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer

Chia, S., Gandhi, S., Joy, A. A., Edwards, S., Gorr, M., Hopkins, S. P., Kondejewski, J., Ayoub, J.-P., Califaretti, N., Rayson, D., et al. (2015) · Current Oncology · doi:10.3747/co.22.2393 · Cited by 118

Stress granule subtypes: an emerging link to neurodegeneration

Advani, V. M., & Ivanov, P. V. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03565-0 · Cited by 118

MEK and PI3K inhibition in solid tumors: rationale and evidence to date

Jokinen, E., & Koivunen, J. P. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015571111 · Cited by 118

Therapeutic targeting of the mTOR ‐signalling pathway in cancer: benefits and limitations

Moschetta, M., Reale, A., Marasco, C., Vacca, A., & Carratù, M. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12749 · Cited by 119

New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis

Comas, M., Toshkov, I. A., Kuropatwinski, K. K., Chernova, O. B., Polinsky, A., Blagosklonny, M. V., Gudkov, A. V., & Antoch, M. P. (2012) · Aging · doi:10.18632/aging.100496 · Cited by 117

Mechanistic Target of Rapamycin Complex 2 Protects the Heart From Ischemic Damage

Völkers, M., Konstandin, M. H., Doroudgar, S., Toko, H., Quijada, P. J., Din, S., Joyo, A. Y., Ornelas, L., Samse, K., Thuerauf, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.003638 · Cited by 116

Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth

Azoulay‐Alfaguter, I., Elya, R., Avrahami, L., Katz, A., & Eldar-Finkelman, H. (2014) · Oncogene · doi:10.1038/onc.2014.390 · Cited by 114

Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer

Gadgeel, S. M., & Wozniak, A. J. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.12.001 · Cited by 116

Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy

Shaik, F., Cuthbert, G. A., Homer‐Vanniasinkam, S., Muench, S. P., Ponnambalam, S., & Harrison, M. A. (2020) · Biomolecules · doi:10.3390/biom10121673 · Cited by 114

Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission

van der Hoeven, D., Cho, K.-J., Ma, X., Chigurupati, S., Parton, R. G., & Hancock, J. F. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00884-12 · Cited by 113

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

Janes, M. R., Vu, C., Mallya, S., Shieh, M., Limon, J. J., Li, L., Jessen, K., Martin, M., Ren, P., Lilly, M. B., et al. (2012) · Leukemia · doi:10.1038/leu.2012.276 · Cited by 110

Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2–Deficient Target Cell Types

James, M. F., Stivison, E., Beauchamp, R. L., Han, S., Li, H., Wallace, M. R., Gusella, J. F., Stemmer-Rachamimov, A. O., & Ramesh, V. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0425-t · Cited by 112

Potential therapeutic effects of mTOR inhibition in atherosclerosis

Kurdi, A., Meyer, G. R. Y. D., & Martinet, W. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12820 · Cited by 111

Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer

Li, B., & Simon, M. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3629 · Cited by 108

The challenges of tumor genetic diversity

Mroz, E. A., & Rocco, J. W. (2016) · Cancer · doi:10.1002/cncr.30430 · Cited by 112

mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice

Thiem, S., Pierce, T. P., Palmieri, M., Putoczki, T. L., Büchert, M., Preaudet, A., Farid, R., Love, C., Catimel, B., Lei, Z., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65086 · Cited by 104

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity

Faes, S., Demartines, N., & Dormond, O. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1726078 · Cited by 104

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

Ross, J. S., Wang, K., Elkadi, O., Tarasen, A. J., Foulke, L., Sheehan, C. E., Otto, G. A., Palmer, G. A., Yelensky, R., Lipson, D., et al. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202447 · Cited by 104

Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target

Zhou, J., Zhu, G., Huang, J. X., Li, L., Du, Y., Gao, Y., Wu, D., Wang, X., Hsieh, J., He, D., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.006 · Cited by 104

Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study

Yu, T., Chuang, Y., Yu, M., Chen, C., Yang, C., Huang, S., Lin, C., Shu, K., & Kao, C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30250-9 · Cited by 104

mTOR as a therapeutic target in patients with gastric cancer

Al-Batran, S. E., Ducreux, M. P., & Ohtsu, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26396 · Cited by 101

Advances in pathogenic mechanisms and management of radiation-induced fibrosis

Wang, B., Wei, J., Meng, L., Wang, H., Qu, C., Chen, X., Xin, Y., & Jiang, X. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109560 · Cited by 100

Targeting LKB1 in Cancer – Exposing and Exploiting Vulnerabilities

Momcilovic, M., & Shackelford, D. B. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.261 · Cited by 97

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

Cerma, K., Piacentini, F., Moscetti, L. I., Barbolini, M., Canino, F., Tornincasa, A., Caggia, F., Cerri, S., Molinaro, A., Dominici, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010109 · Cited by 102

Atypical Protein Kinase Cι as a human oncogene and therapeutic target

Parker, P. J., Justilien, V., Riou, P., Linch, M. D., & Fields, A. P. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.023 · Cited by 95

Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer

Wang, C., Cigliano, A., Delogu, S., Armbruster, J., Dombrowski, F., Evert, M., Chen, X., & Calvisi, D. F. (2013) · Cell Cycle · doi:10.4161/cc.25099 · Cited by 94

ATG4B promotes colorectal cancer growth independent of autophagic flux

Liu, P., Leung, C., Chang, Y.-H., Cheng, J., Chen, J., Weng, C.-J., Tsai, K., Hsu, C.-J., Liu, Y., Hsu, P., et al. (2014) · Autophagy · doi:10.4161/auto.29556 · Cited by 89

Controversies around the function of LARP1

Berman, A. J., Thoreen, C. C., Dedeić, Z., Chettle, J., Roux, P. P., & Blagden, S. P. (2020) · RNA Biology · doi:10.1080/15476286.2020.1733787 · Cited by 83

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer

Treilleux, I., Arnedos, M., Cropet, C., Wang, Q., Ferrero, J.-M., Abadie‐Lacourtoisie, S., Lévy, C., Legouffe, É., Lortholary, A. H., Pujade-Lauraine, É., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu497 · Cited by 87

Regulation of Blood–Testis Barrier (BTB) Dynamics during Spermatogenesis via the “Yin” and “Yang” Effects of Mammalian Target of Rapamycin Complex 1 (mTORC1) and mTORC2

Mok, K., Mruk, D. D., & Cheng, C. Y. (2013) · International review of cytology · doi:10.1016/b978-0-12-407704-1.00006-3 · Cited by 84

4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N‐Ras proto‐oncogenes in mice

Wang, C., Cigliano, A., Jiang, L., Li, X., Fan, B., Pilo, M. G., Liu, Y., Gui, B., Sini, M., Smith, J. W., et al. (2014) · Hepatology · doi:10.1002/hep.27396 · Cited by 86

Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors

Zaza, G., Tomei, P., Ria, P., Granata, S., Boschiero, L., & Lupo, A. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/403280 · Cited by 83

Everolimus in the Treatment of Metastatic Breast Cancer

Royce, M., & Osman, D. I. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s29268 · Cited by 86

4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer

Wang, Z., Feng, X., Molinolo, A., Martı́n, D., Vitale-Cross, L. A., Nohata, N., Ando, M., Wahba, A., Amornphimoltham, P., Wu, X., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1220 · Cited by 84

Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation

Deng, L. H., Qian, G., Zhang, S., Zheng, H., Fan, S., Lesinski, G. B., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. (2019) · Oncogene · doi:10.1038/s41388-019-0877-4 · Cited by 85

mTORC1‐ and mTORC2‐interacting proteins keep their multifunctional partners focused

Bracho‐Valdés, I., Moreno‐Alvarez, P., Valencia‐Martínez, I., Robles‐Molina, E., Chávez‐Vargas, L., & Vázquez‐Prado, J. (2011) · IUBMB Life · doi:10.1002/iub.558 · Cited by 84

Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism

Iwata, T., Ramírez, J. A., Tsang, M., Park, H., Margineantu, D. H., Hockenbery, D. M., & Iritani, B. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600492 · Cited by 84

Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis

Boers-Doets, C. B., Raber‐Durlacher, J. E., Treister, N. S., Epstein, J. B., Arends, A. B., Wiersma, D. R., Lalla, R. V., Logan, R. M., van Erp, N. P., & Gelderblom, H. A. J. (2013) · Future Oncology · doi:10.2217/fon.13.141 · Cited by 81

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

Gökmen‐Polar, Y., Liu, Y., Toroni, R. A., Sanders, K. L., Mehta, R. J., Badve, S., Rommel, C., & Sledge, G. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2298-8 · Cited by 80

Autophagy in Pulmonary Diseases

Nakahira, K., Pabon Porras, M. A., & Choi, A. M. K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201512-2468so · Cited by 78

Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas

Khan, T., Relitti, N., Brindisi, M., Magnano, S., Zisterer, D. M., Gemma, S., Butini, S., & Campiani, G. (2019) · Medicinal Research Reviews · doi:10.1002/med.21646 · Cited by 79

mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition

Limon, J. J., So, L., Jellbauer, S., Chiu, H., Corado, J., Sykes, S. M., Raffatellu, M., & Fruman, D. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407104111 · Cited by 76

mTOR co-targeting strategies for head and neck cancer therapy

Wang, Z., Valera, J. L. C., Zhao, X., Chen, Q., & Gutkind, J. S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9688-7 · Cited by 79

Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML

Herschbein, L., & Liesveld, J. L. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.11.006 · Cited by 76

Clinical management of obese patients with cancer

Tao, W., & Lagergren, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.120 · Cited by 77

Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy

Johnson, S. A., & Spurney, R. F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2015 · Cited by 76

The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5′TOP sequence

Lahr, R. M., Mack, S. M., Heroux, A., Blagden, S. P., Bousquet‐Antonelli, C., Deragon, J., & Berman, A. J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv748 · Cited by 74

Targeting the mTOR signaling network in cancer

Chiang, G. G., & Abraham, R. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.001 · Cited by 332

Therapeutic targeting of the mTOR ‐signalling pathway in cancer: benefits and limitations

Moschetta, M., Reale, A., Marasco, C., Vacca, A., & Carratù, M. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12749 · Cited by 119

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77

Revisiting mTOR inhibitors as anticancer agents

Teng, Q., Ashar, Y. V., Gupta, P., Gadee, E., Fan, Y., Reznik, S. E., Wurpel, J. N. D., & Chen, Z. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.030 · Cited by 28

[mTOR signal pathway and its inhibitors in antitumor therapy: a review].

Huang, J., & Lin, T. Y. (2007) · PubMed · Cited by 5